Table 3.
Hazard ratios of overall survival in R-CHOP–treated patients and agreement with original study regarding predictive capacity
| Gene* | HR (95% CI)† | Agree with trend in original study |
|---|---|---|
| BCL6 | 0.62 (0.44-0.87) | Yes |
| GCET1 (SERPINA9) | 0.62 (0.41-0.92) | Yes |
| GCET2 | 0.93 (0.66-1.31) | Yes |
| HLA-DPA1 | 0.77 (0.56-1.05) | Yes |
| HLA-DQA1 | 0.65 (0.45-0.93) | Yes |
| HLA-DRA | 0.91 (0.67-1.24) | Yes |
| HLA-DRB | 0.71 (0.53-0.95) | Yes |
| ACTN1 | 0.62 (0.43-0.89) | Yes |
| COL3A1 | 0.67 (0.47-0.97) | Yes |
| CTGF | 0.80 (0.56-1.14) | Yes |
| FN1 | 0.73 (0.51-1.04) | Yes |
| FAM38A | 0.85 (0.58-1.26) | Yes |
| PLAU | 0.56 (0.40-0.79) | Yes |
| MYC | 1.64 (1.16-2.31) | Yes |
| C20ORF155 | 1.03 (0.73-1.47) | No |
| NPM3 | 1.22 (0.84-1.76) | Yes |
| BMP6 | 0.86 (0.59-1.23) | No |
| LMO2 | 0.62 (0.43-0.90) | Yes |
| BCL2 | 1.11 (0.77-1.60) | Yes |
| CCL3 | 0.82 (0.58-1.18) | No |
| CCND2 | 1.23 (0.85-1.77) | Yes |
| DRP2 | 0.94 (0.65-1.35) | Yes |
| PRKCB1 | 0.99 (0.69-1.42) | No |
| PDCD4 | 1.53 (1.07-2.21) | Yes |
| MAP1B | 0.94 (0.66-1.33) | Yes |
| TLE1 | 1.16 (0.81-1.65) | Yes |
| SLC25A13 | 0.90 (0.63-1.28) | Yes |
| PDE4B | 1.17 (0.81-1.68) | Yes |
| B4GALT1 | 0.82 (0.57-1.16) | No |
| PRKCG | 1.02 (0.69-1.51) | Yes |
| OVGP1 | 1.03 (0.73-1.47) | Yes |
| NR4A3 | 0.80 (0.55-1.15) | Yes |
| ZNF212 | 1.04 (0.74-1.48) | Yes |
| HTR2B | 0.76 (0.49-1.18) | Yes |
| CAT | 0.99 (0.70-1.41) | No |
| SOD2 | 0.64 (0.45-0.92) | Yes |
HR indicates hazard ratio; and CI, confidence interval.
*
Standardized to normal (0, 1) distribution.
†
HR of 1 indicates no effect on risk; HR between 0 and 1, good risk; HR greater than 1, poor risk.